Praxis precision medicines adds development expertise to board of directors with appointment of jeffrey chodakewitz, m.d.

Cambridge, mass., april 15, 2021 (globe newswire) -- praxis precision medicines, inc. (nasdaq: prax), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (cns) disorders characterized by neuronal imbalance, today announced the appointment of jeffrey chodakewitz, m.d., to its board of directors. the company also announced that nicholas galakatos, ph.d., and kiran reddy, m.d., have resigned from its board of directors.
PRAX Ratings Summary
PRAX Quant Ranking